Related Experiment Video

Updated: May 27, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Recommendations on management of EGFR inhibitor-induced skin toxicity: a systematic review

J M Baas1, L L Krens, H-J Guchelaar

  • 1Department of Clinical Oncology, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands. j.m.baas@lumc.nl

Cancer Treatment Reviews
|November 22, 2011
PubMed

Insights

Epidermal growth factor receptor (EGFR) inhibitors can cause skin toxicity, impacting patient quality of life. Managing this toxicity is crucial for maintaining treatment efficacy and patient well-being.

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • Epidermal growth factor receptor (EGFR) inhibitors like cetuximab and panitumumab are effective cancer treatments.
  • EGFR is expressed in the skin, leading to frequent skin toxicities with these therapies.
  • Skin toxicity can negatively affect patient quality of life and necessitate treatment adjustments.

Purpose of the Study:

  • To review and discuss current trials and case studies on managing EGFR inhibitor-induced skin toxicity.
  • To highlight the importance of managing skin toxicity for maintaining anti-tumor efficacy and patient quality of life.

Main Methods:

  • Review of available clinical trials and case studies.
  • Discussion of management strategies for EGFR inhibitor-induced skin toxicity.

Main Results:

  • A correlation between skin toxicity and anti-tumor activity has been observed in phase III studies.
  • Evidence-based guidelines for managing EGFR inhibitor-induced skin toxicity are currently limited due to a scarcity of randomized controlled trials.

Conclusions:

  • Effective management of EGFR inhibitor-induced skin toxicity is essential for optimizing anti-tumor efficacy and preserving patient quality of life.
  • Further research, including randomized controlled trials, is needed to establish evidence-based guidelines for managing these toxicities.

Related Concept Videos

Acne Infection01:27

Acne Infection

Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...